A long-term, extended treatment study of aripiprazole in pediatric patients with schizophrenia

A multicenter, open-label, long-term safety study of aripiprazoleorally administered over 52 weeks in patients who complete a short-term treatment study of aripiprazole in pediatric patients with schizophrenia (031-09-003 study)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221113

Enrollment

Registered

2010-05-27

Start date

2010-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : aripiprazole INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with a diagnosis of schizophrenia according to DSM-IV-TR 2) Male and female patients aged 13-17 years 3) Patients completing the 031-09-003 study

Exclusion criteria

Exclusion criteria: 1) Patients who have a diagnosis of any other disease except schizophrenia, according to DSM-IV-TR 2) Patients who fall under a contraindication listed in the ABILIFY package insert

Design outcomes

Primary

Measure	Time frame
PANSS total sore change from baseline	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026